On Tuesday, Exact Sciences Corp (NASDAQ: EXAS) opened lower -2.28% from the last session, before settling in for the closing price of $51.33. Price fluctuations for EXAS have ranged from $40.62 to $79.62 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 43.88% annually for the last half of the decade. Company’s average yearly earnings per share was noted -3.33% at the time writing. With a float of $182.28 million, this company’s outstanding shares have now reached $185.08 million.
In an organization with 6600 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 72.1%, operating margin of -7.18%, and the pretax margin is -7.82%.
Exact Sciences Corp (EXAS) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Diagnostics & Research industry is another important factor to consider. The insider ownership of Exact Sciences Corp is 1.51%, while institutional ownership is 98.07%. The most recent insider transaction that took place on Oct 08 ’24, was worth 65,030. In this transaction EVP, GM, Precision Oncology of this company sold 929 shares at a rate of $70.00, taking the stock ownership to the 12,758 shares. Before that another transaction happened on Oct 08 ’24, when Company’s Officer proposed sale 929 for $70.00, making the entire transaction worth $65,030.
Exact Sciences Corp (EXAS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -3.33% per share during the next fiscal year.
Exact Sciences Corp (NASDAQ: EXAS) Trading Performance Indicators
Check out the current performance indicators for Exact Sciences Corp (EXAS). In the past quarter, the stock posted a quick ratio of 1.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.45. Likewise, its price to free cash flow for the trailing twelve months is 94.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.17, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -0.26 in one year’s time.
Technical Analysis of Exact Sciences Corp (EXAS)
Let’s dig in a bit further. During the last 5-days, its volume was 6.8 million. That was better than the volume of 2.63 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 6.40%. Additionally, its Average True Range was 3.50.
During the past 100 days, Exact Sciences Corp’s (EXAS) raw stochastic average was set at 29.61%, which indicates a significant increase from 8.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 109.06% in the past 14 days, which was higher than the 70.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $66.35, while its 200-day Moving Average is $58.60. However, in the short run, Exact Sciences Corp’s stock first resistance to watch stands at $51.43. Second resistance stands at $52.71. The third major resistance level sits at $54.41. If the price goes on to break the first support level at $48.45, it is likely to go to the next support level at $46.75. The third support level lies at $45.47 if the price breaches the second support level.
Exact Sciences Corp (NASDAQ: EXAS) Key Stats
There are currently 185,076K shares outstanding in the company with a market cap of 9.28 billion. Presently, the company’s annual sales total 2,500 M according to its annual income of -204,150 K. Last quarter, the company’s sales amounted to 708,660 K and its income totaled -38,240 K.
